Pyxis Oncology (PYXS) Common Equity (2020 - 2026)
Pyxis Oncology (PYXS) posted quarterly Common Equity of $53.4 million for Q4 2025, down 55.77% year-over-year from $120.8 million in Q4 2024, and down 22.35% quarter-over-quarter from $68.8 million in Q3 2025.
Pyxis Oncology (PYXS) Common Equity (2020 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported Common Equity for 6 consecutive years, with $53.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Common Equity fell 55.77% year-over-year to $53.4 million; the TTM figure through Dec 2025 stood at $53.4 million (down 55.77% YoY), while the FY2025 annual figure was $53.4 million, down 55.77% from the prior year.
- Common Equity eased to $53.4 million in Q4 2025 per PYXS's latest filing, from $68.8 million in the prior quarter.
- Across five years, Common Equity topped out at $261.3 million in Q4 2021 and bottomed at -$71.4 million in Q3 2021.
- Historically, Common Equity has averaged $119.0 million across 5 years, with a median of $141.6 million in 2023.
- On a YoY basis, Common Equity climbed as much as 1770.27% in 2021 and fell as far as 544.35% in 2021.
- Pyxis Oncology's Common Equity stood at $261.3 million in 2021, then slumped by 38.46% to $160.8 million in 2022, then decreased by 21.84% to $125.7 million in 2023, then dropped by 3.94% to $120.8 million in 2024, then plunged by 55.77% to $53.4 million in 2025.
- Business Quant data shows PYXS's Common Equity at $53.4 million in Q4 2025, $68.8 million in Q3 2025, and $87.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.24 Bn | 131.39 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.01 Bn | 78.02 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.61 Bn | 60.42 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.92 Bn | 51.78 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.77 Bn | 9.38 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 9.79 Bn |
| 10 | Pyxis Oncology | 197.73 Mn | 164.74 Mn | - | 11.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.44 Mn |
| Dec 31, 2025 | 53.41 Mn |
| Sep 30, 2025 | 68.78 Mn |
| Jun 30, 2025 | 87.64 Mn |
| Mar 31, 2025 | 103.10 Mn |
| Dec 31, 2024 | 120.75 Mn |
| Sep 30, 2024 | 153.68 Mn |
| Jun 30, 2024 | 169.79 Mn |
| Mar 31, 2024 | 184.16 Mn |
| Dec 31, 2023 | 125.70 Mn |
| Sep 30, 2023 | 137.95 Mn |
| Jun 30, 2023 | 145.28 Mn |
| Mar 31, 2023 | 152.16 Mn |
| Dec 31, 2022 | 160.82 Mn |
| Sep 30, 2022 | 188.75 Mn |
| Jun 30, 2022 | 211.97 Mn |
| Mar 31, 2022 | 233.51 Mn |
| Dec 31, 2021 | 261.31 Mn |
| Sep 30, 2021 | -71.44 Mn |
| Jun 30, 2021 | -57.59 Mn |